97.99
+2.215(+2.31%)
Currency In USD
| Previous Close | 95.78 |
| Open | 96.64 |
| Day High | 98.41 |
| Day Low | 93.82 |
| 52-Week High | 124.49 |
| 52-Week Low | 29.17 |
| Volume | 2.31M |
| Average Volume | 3.4M |
| Market Cap | 18.94B |
| PE | -18.88 |
| EPS | -5.19 |
| Moving Average 50 Days | 92.25 |
| Moving Average 200 Days | 56.47 |
| Change | 2.22 |
If you invested $1000 in Revolution Medicines, Inc. (RVMD) since IPO date, it would be worth $3,390.66 as of February 11, 2026 at a share price of $97.99. Whereas If you bought $1000 worth of Revolution Medicines, Inc. (RVMD) shares 5 years ago, it would be worth $1,951.6 as of February 11, 2026 at a share price of $97.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 04, 2026 9:05 PM GMT
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith,
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
GlobeNewswire Inc.
Jan 29, 2026 1:00 PM GMT
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient was dosed in its first-in-h
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
GlobeNewswire Inc.
Jan 08, 2026 1:00 PM GMT
Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) who have been previously treated with anti-PD-1/PD-L1 therapy and pla